CeriBell (NASDAQ:CBLL) CEO Sells 2,199 Shares

Key Points

• CEO insider selling: CeriBell CEO Xingjuan Chao sold 2,199 shares at an average of $25.00, worth $54,975, reducing her ownership by 0.27%. She also sold 31,415 shares the following day and has made additional sizable sales in recent months.
• Stock and financial performance: CeriBell shares traded at $24.31, near their 52-week high of $25.33, but the company reported a quarterly loss of $0.51 per share, missing estimates, despite revenue exceeding expectations.
• Analyst and institutional sentiment: Several funds increased their positions, while analysts raised price targets and maintained a generally positive outlook. The stock carries a “Moderate Buy” consensus rating, with an average price target of $22.40.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 2,199 shares of the firm's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $25.00, for a total value of $54,975.00. Following the completion of the sale, the chief executive officer owned 819,214 shares in the company, valued at $20,480,350. The trade was a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total transaction of $786,317.45.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total transaction of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Stock Performance

NASDAQ:CBLL traded down $0.58 during mid-day trading on Thursday, hitting $24.31. The stock had a trading volume of 262,277 shares, compared to its average volume of 346,888. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The company has a 50 day simple moving average of $19.30 and a 200-day simple moving average of $19.16. The stock has a market capitalization of $932.97 million, a price-to-earnings ratio of -13.81 and a beta of 0.81. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, research analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of CeriBell by 6,424.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company's stock worth $7,117,000 after buying an additional 374,179 shares in the last quarter. Rhumbline Advisers boosted its stake in CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company's stock valued at $614,000 after buying an additional 17,177 shares in the last quarter. New York State Common Retirement Fund boosted its stake in CeriBell by 148.6% during the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company's stock valued at $163,000 after buying an additional 5,200 shares in the last quarter. Quantbot Technologies LP grew its holdings in CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company's stock worth $290,000 after acquiring an additional 6,401 shares during the period. Finally, Invesco Ltd. bought a new stake in CeriBell in the second quarter worth about $197,000.

Analyst Ratings Changes

Several analysts have weighed in on CBLL shares. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. BTIG Research increased their price target on CeriBell from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday. Barclays raised CeriBell to a "neutral" rating in a report on Tuesday. Finally, Weiss Ratings raised shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.40.

About CeriBell

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source